• Home
  • 公司简介
  • Human Cardiomyocytes

沿革 NEXEL简介 沿革

2026’s

  • 09s
    "AI-Integrated hiPSC-CM Functional Cardiotoxicity Screening Platform” FDA iSTand LOI ACCEPTANCE
    07s
    Cardiosight®-S approved for FDA iSTand LOI as a NAMs DDT for cardiac safety assessment
    05s
    Signed global distribution and strategic partnership MOU with ChemPartner (China)
    04s
    Published paper on precision cardiotoxicity evaluation combining cardiomyocytes and AI prediction (Archives of Toxicology, IF: 10.9)
    03s
    Registered US patent for cardiac safety evaluation using cardiomyocytes
    03s
    Filed Korean patent for impedance-based precision cardiac safety testing method using cardiomyocytes
    03s
    Filed Korean patent for impedance-based precision hepatotoxicity testing method using hepatocytes
    03s
    Commenced mass production of heart organoids
    03s
    Signed JV establishment contract among NEXEL, CMIC, and DNP for marketing & business of iPSC-based products
    01s
    Signed Master Services Agreement (MSA) with Celltrion for drug evaluation utilizing hiPSC models

2025’s

  • 10s
    Hosted 1st NEXEL Innovation Talk – New ERA of Organoid (1st NEXEL Academic Event)
    08s
    Filed Korean patent for micropattern development to improve cardiomyocyte maturation
    08s
    Filed Korean patent for assessing drug effects on cardiomyocyte sodium ion channels
    07s
    Signed MOU with Korea Brain Research Institute (KBRI) for brain organoid research and commercial technology development
    07s
    Commenced mass production of cardiac organoids
    03s
    Registered Korean patent for cardiac organoid drug evaluation method
    01s
    Converted U.S. subsidiary Celogics into a 100% wholly-owned subsidiary

2024’s

  • 12s
    Cardiosight®-S listed in "Comprehensive Cardiac Arrhythmia Evaluation Guidelines" published by MFDS
    12s
    Registered Japanese patent for cardiac/cardiomyocyte organoid differentiation induction methods
    06s
    Registered Korean patent for cardiac/cardiomyocyte organoid differentiation induction methods
    05s
    Signed non-exclusive agency contract with Scientist.com (USA) for NEXEL product sales
    04s
    Awarded Best Poster Award at 2024 Korean Organoid Society
    04s
    Signed tech transfer and business alliance agreement with DNP (Japan) (JPY 250M)
    04s
    Signed non-exclusive agency contract with PELO Biotech (Germany) for NEXEL product sales (hiPSC-derived products)
    01s
    Registered Korean patent for cardiac safety evaluation using cardiomyocytes

2023’s

  • 11s
    Filed Korean patent for heart disease modeling using cardiac organoids
    11s
    Awarded KEIT President Award for Outstanding R&D Company in Bio-Health at 2023 Bio Industry Day (MOTIE)
    09s
    Secured JPY 100M strategic investment and signed business cooperation agreement with CMIC (Japan's largest CRO)
    08s
    Awarded Best Poster Award at 2023 Korean Society for Stem Cell Research
    06s
    Filed Chinese patent for cardiac safety evaluation using cardiomyocytes
    01s
    Filed US, European, and Japanese patents for cardiac organoid drug evaluation method
    01s
    Filed US, European, Japanese, and Chinese patents for myocardial organoids and a method for inducing differentiation into cardiac organoids

2022’s

  • 12s
    Registered patent for vascular dementia treatment technology using neurons
    12s
    Signed technology transfer agreement with KIT for hiPSC-derived liver organoid manufacturing technology
    12s
    Filed Korean patent for cardiac organoid drug evaluation method
    04s
    Obtained ISO 17025 certification and KOLAS accreditation for drug evaluation assay using hiPSC-CMs

2021’s

  • 12s
    Participated in ICH Guideline Revision / HESI research; NEXEL Cardiosight®-S cardiomyocytes selected and supplied as standard cells
    10s
    Established joint venture Celogics in Seattle, USA, with Curi Bio
    10s
    Awarded Best Poster Award at 2021 Korean Organoid Society
    07s
    Awarded Best Poster Award at 2021 Korean Society for Stem Cell Research
    04s
    Participated in publishing "Guide to Cardiovascular Safety Pharmacology Assessment" hosted by MFDS

2020’s

  • 01s
    Officially launched hiPSC model-based drug evaluation service (NeXST)

2019’s

  • 06s
    Registered patent for mass production differentiation of cardiomyocytes

2018’s

  • 06s
    Obtained INNOBIZ Certification
    05s
    Acquired commercial license utilizing human induced pluripotent stem cells from iPS Academia Japan (Kyoto University)
    03s
    Launched hiPSC-derived cardiomyocytes (Cardiosight®-S) and neurons (Neurosight®-S)
    03s
    Obtained ISO 9001 certification for hiPSC-derived functional cell product manufacturing

2017’s

  • 11s
    Launched hiPSC-derived hepatocyte product (Hepatosight®-S)

2016’s

  • 12s
    Acquired patent technology transfer from Korea University Research & Business Foundation (6 patents)
    11s
    Acquired technology transfer from KIT for stem cell-derived cardiomyocyte differentiation induction methods
    03s
    Certified as an Affiliated Research Institute
    02s
    Certified as a Venture Business

2015’s

  • 05s
    Renamed to NEXEL Co., Ltd.

2013’s

  • 03s
    Signed research cooperation MOU with Korea University Anam Hospital

2012’s

  • 09s
    Established NEXEL Bio
Beyond conventional boundaries,
we deliver a bold new paradigm.

  • iPSC technology联系方式

    联系方式信息

    • 地址: 韩国首尔特别市江西区麻谷东路55，8楼（07802）

    • 营业执照号码: 109-86-37282
    • CEO: Choongseong Han

    • 电话: +82-2-2088-8886
    • 传真: +82-2-2088-8884
    • 电子邮箱: support@nexel.co.kr